100 related articles for article (PubMed ID: 25109437)
1. Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.
Kagota S; Maruyama K; Wakuda H; McGuire JJ; Yoshikawa N; Nakamura K; Shinozuka K
Vascul Pharmacol; 2014 Oct; 63(1):46-54. PubMed ID: 25109437
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Nitric Oxide Synthase Activation via Protease-Activated Receptor 2 Is Involved in the Preserved Vasodilation in Aortas from Metabolic Syndrome Rats.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
J Vasc Res; 2015; 52(4):232-43. PubMed ID: 26760532
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
Kagota S; Tada Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
Can J Physiol Pharmacol; 2011 May; 89(5):355-64. PubMed ID: 21619437
[TBL] [Abstract][Full Text] [Related]
4. Age-related changes to vascular protease-activated receptor 2 in metabolic syndrome: a relationship between oxidative stress, receptor expression, and endothelium-dependent vasodilation.
Maruyama K; Kagota S; McGuire JJ; Wakuda H; Yoshikawa N; Nakamura K; Shinozuka K
Can J Physiol Pharmacol; 2017 Apr; 95(4):356-364. PubMed ID: 28103056
[TBL] [Abstract][Full Text] [Related]
5. Panax notoginseng saponins ameliorate impaired arterial vasodilation in SHRSP.Z-Lepr(fa) /lzmDmcr rats with metabolic syndrome.
Wu T; Sun J; Kagota S; Maruyama K; Wakuda H; Shinozuka K
Clin Exp Pharmacol Physiol; 2016 Apr; 43(4):459-67. PubMed ID: 26784885
[TBL] [Abstract][Full Text] [Related]
6. Chronic oxidative-nitrosative stress impairs coronary vasodilation in metabolic syndrome model rats.
Kagota S; Maruyama K; Tada Y; Fukushima K; Umetani K; Wakuda H; Shinozuka K
Microvasc Res; 2013 Jul; 88():70-8. PubMed ID: 23571030
[TBL] [Abstract][Full Text] [Related]
7. Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa) /IzmDmcr rats with metabolic syndrome.
Kagota S; Fukushima K; Umetani K; Tada Y; Nejime N; Nakamura K; Mori H; Sugimura K; Kunitomo M; Shinozuka K
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1035-43. PubMed ID: 20659132
[TBL] [Abstract][Full Text] [Related]
8. Time-Dependent Differences in the Influence of Perivascular Adipose Tissue on Vasomotor Functions in Metabolic Syndrome.
Kagota S; Iwata S; Maruyama K; McGuire JJ; Shinozuka K
Metab Syndr Relat Disord; 2017 Jun; 15(5):233-239. PubMed ID: 28358621
[TBL] [Abstract][Full Text] [Related]
9. Progression of Time-Dependent Changes to the Mechanisms of Vasodilation by Protease-Activated Receptor 2 in Metabolic Syndrome.
Maruyama K; McGuire JJ; Kagota S
Biol Pharm Bull; 2017; 40(12):2039-2044. PubMed ID: 29199228
[TBL] [Abstract][Full Text] [Related]
10. Perivascular Adipose Tissue-Enhanced Vasodilation in Metabolic Syndrome Rats by Apelin and
Kagota S; Maruyama-Fumoto K; Iwata S; Shimari M; Koyanagi S; Shiokawa Y; McGuire JJ; Shinozuka K
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597883
[TBL] [Abstract][Full Text] [Related]
11. Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice.
Chia E; Kagota S; Wijekoon EP; McGuire JJ
BMC Pharmacol; 2011 Sep; 11():10. PubMed ID: 21955547
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular remodeling and metabolic abnormalities in SHRSP.Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome.
Ueno T; Takagi H; Fukuda N; Takahashi A; Yao EH; Mitsumata M; Hiraoka-Yamamoto J; Ikeda K; Matsumoto K; Yamori Y
Hypertens Res; 2008 May; 31(5):1021-31. PubMed ID: 18712058
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.
Hughes KH; Wijekoon EP; Valcour JE; Chia EW; McGuire JJ
Can J Physiol Pharmacol; 2013 Apr; 91(4):295-305. PubMed ID: 23627841
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome.
Kagota S; Maruyama-Fumoto K; Shimari M; McGuire JJ; Shinozuka K
Cardiovasc Drugs Ther; 2019 Oct; 33(5):501-509. PubMed ID: 31420755
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery.
Matsumoto T; Ishida K; Taguchi K; Kobayashi T; Kamata K
Peptides; 2009 Sep; 30(9):1729-34. PubMed ID: 19540892
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats.
Smeda JS; McGuire JJ; Daneshtalab N
Peptides; 2010 Feb; 31(2):227-37. PubMed ID: 19954757
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Endothelial Transient Receptor Potential Vanilloid Type 4 Channel and Small-Conductance of Ca2+-Activated K+ Channels Underpins Impaired Endothelium-Dependent Hyperpolarization in Hypertension.
Seki T; Goto K; Kiyohara K; Kansui Y; Murakami N; Haga Y; Ohtsubo T; Matsumura K; Kitazono T
Hypertension; 2017 Jan; 69(1):143-153. PubMed ID: 27872234
[TBL] [Abstract][Full Text] [Related]
18. Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice.
Kagota S; Chia E; McGuire JJ
Br J Pharmacol; 2011 Sep; 164(2):358-71. PubMed ID: 21426317
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin.
López-Farré A; Rodriguez-Feo JA; García-Colis E; Gomez J; López-Blaya A; Fortes J; de Andrés R; Rico L; Casado S
J Hypertens; 2002 Mar; 20(3):463-70. PubMed ID: 11875314
[TBL] [Abstract][Full Text] [Related]
20. Impairment of Protease-Activated Receptor 2-Induced Relaxation of Aortas of Aged Spontaneously Hypertensive Rat.
Ando M; Matsumoto T; Kobayashi S; Iguchi M; Taguchi K; Kobayashi T
Biol Pharm Bull; 2018; 41(5):815-819. PubMed ID: 29709920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
